US Biomax, Inc.

FMC405

Multiple organ carcinoma frozen tissue array, including TNM and clinical stage, 40 cases/40 cores, replaced by FMC405a

Microarray Panel:Multiple organ carcinoma frozen tissue microarray, containing 21 cases of breast carcinoma, 9 ovary carcinoma, 3 endometrial cancer, 5 carcinoma of vulva and 2 cervix carcinoma, single core per case
Cores:40
Cases:40
Layout:8 cols × 5 rows
Core Diameter:2 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Tissues were snap frozen in liquid nitrogen immediately after excision and were embedded in OCT. The array sections are 5-8 µm in thickness, mounted on positively charged glass slides, and briefly fixed by cold acetone.


Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
12345678
A Bre Bre Bre Bre Bre Bre Bre Bre
B Bre Bre Bre Bre Bre Bre Bre Bre
C Bre Bre Bre Bre Bre Ova Ova Ova
D Ova Ova Ova Ova Ova Ova End End
E End Vul Vul Vul Vul Vul Cer Cer
Legend: Bre - Breast, Cer - Cervix, End - Endometrium, Ova - Ovary, Vul - Vulva

- Malignant tumor, - Malignant tumor (stage 0), - Malignant tumor (stage II), - Malignant tumor (stage IIIa), - Malignant tumor (stage IIIb), - Malignant tumor (stage IIa), - Malignant tumor (stage IIb), - Malignant tumor (stage IV), - Malignant tumor (stage Ia), - Malignant tumor (stage Ia1), - Malignant tumor (stage Ia2), - Malignant tumor (stage Ib)

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Stage TNM Type †
A1 1 F 57 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
A2 2 F 45 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
A3 3 F 51 Breast Invasive ductal carcinoma IIIa T2N2M0 Malignant
A4 4 F 42 Breast Invasive ductal carcinoma IIIa T2N2M0 Malignant
A5 5 F 51 Breast Invasive lobular carcinoma IIIa T2N2M0 Malignant
A6 6 F 33 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
A7 7 F 45 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
A8 8 F 38 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
B1 9 F 39 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
B2 10 F 52 Breast Invasive ductal carcinoma IIb T2N1M0 Malignant
B3 11 F 59 Breast Non-Hodgkin's lymphoma IIa T2N0M0 Malignant
B4 12 F 45 Breast Invasive ductal carcinoma IIIa T2N2M0 Malignant
B5 13 F 44 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
B6 14 F 42 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
B7 15 F 42 Breast Invasive ductal carcinoma(no) IIa T2N0M0 Malignant
B8 16 F 53 Breast Invasive lobular carcinoma IIIa T2N2M0 Malignant
C1 17 F 45 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
C2 18 F 47 Breast Invasive ductal carcinoma IIb T2N1M0 Malignant
C3 19 F 36 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
C4 20 F 58 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
C5 21 F 52 Breast Invasive ductal carcinoma IIa T2N0M0 Malignant
C6 22 F 44 Ovary Adenocarcinoma Malignant
C7 23 F 19 Ovary Adenocarcinoma TxN0M0 Malignant
C8 24 F 45 Ovary Adenocarcinoma IV M1 Malignant
D1 25 F 52 Ovary Adenocarcinoma IIa T2aN0M0 Malignant
D2 26 F 61 Ovary Adenocarcinoma IIIb T3bN0M0 Malignant
D3 27 F 51 Ovary Adenocarcinoma TxN0M0 Malignant
D4 28 F 23 Ovary Non-Hodgkin's lymphoma Malignant
D5 29 F 41 Ovary Adenocarcinoma IIa T2aN0M0 Malignant
D6 30 F 55 Ovary Adenocarcinoma Ib T1bN0M0 Malignant
D7 31 F 47 Endometrium Endometrioid carcinoma Ib T1bN0M0 Malignant
D8 32 F 50 Endometrium Endometrioid carcinoma (smooth muscle tissue) Ib T1bN0M0 Malignant
E1 33 F 46 Endometrium Endometrioid carcinoma Ia T1aN0M0 Malignant
E2 34 F 70 Vulva Squamous cell carcinoma II T2N0M0 Malignant
E3 35 F 70 Vulva Squamous cell carcinoma II T2N0M0 Malignant
E4 36 F 64 Vulva Squamous cell carcinoma II T2N0M0 Malignant
E5 37 F 55 Vulva Squamous cell carcinoma 0 TisN0M0 Malignant
E6 38 F 51 Vulva Squamous cell carcinoma II T2N0M0 Malignant
E7 39 F 60 Cervix Squamous cell carcinoma Ia2 T1a2N0M0 Malignant
E8 40 F 43 Cervix Squamous cell carcinoma (smooth muscle tissue) Ia1 T1a1N0M0 Malignant

† For precise diagnosis, refer to pathology description.

TNM Grading

Primary tumor (T)

  • TX: Primary tumor cannot be assessed
  • T0: No evidence of primary tumor
  • Tis: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no associated invasion of normal breast tissue
    • Tis (DCIS): Ductal carcinoma in situ
    • Tis (LCIS): Lobular carcinoma in situ
    • Tis (Paget's): Paget's disease of the nipple with no tumor. [Note: Paget's disease associated with a tumor is classified according to the size of the tumor.]
  • T1: Tumor 2.0 cm or less in greatest dimension
    • T1mic: Microinvasion 0.1 cm or less in greatest dimension
    • T1a: Tumor more than 0.1 but not more than 0.5 cm in greatest dimension
    • T1b: Tumor more than 0.5 cm but not more than 1.0 cm in greatest dimension
    • T1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension
  • T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension
  • T3: Tumor more than 5.0 cm in greatest dimension
  • T4: Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below.
    • T4a: Extension to chest wall, not including pectoralis muscle
    • T4b: Edema (including peau d'orange) or ulceration of the skin of the breast, or satellite skin nodules confined to the same breast
    • T4c: Both T4a and T4b
    • T4d: Inflammatory carcinoma.
  • Memory Aid for Primary tumor: The two numbers to remember are 2.0 and 5.0
    • T1 is no larger than 2.0 cm
    • T2 > 2.0 - 5.0 cm
    • T3 > 5.0 cm

Regional lymph nodes (N)

  • NX: Regional lymph nodes cannot be assessed (e.g., previously removed)
  • N0: No regional lymph node metastasis
  • N1: Metastasis to movable ipsilateral axillary lymph node(s)
  • N2: Metastasis to ipsilateral axillary lymph node(s) fixed or matted, or in clinically apparent* ipsilateral internal mammary notes in the absence of clinically evident lymph node metastasis
    • N2a: Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to other structures
    • N2b: Metastasis only in clinically apparent* ipsilateral internal mammary nodes and in the absence of clinically evident axillary lymph node metastasis.
  • N3: Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph node involvement, or in clinically apparent* ipsilateral internal mammary lymph node(s) and in the presence of clinically evident axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement
    • N3a: Metastasis in ipsilateral infraclavicular lymph node(s)
    • N3b: Metastasis in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)
    • N3c: Metastasis in ipsilateral supraclavicular lymph node(s)

* [Note: Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination or grossly visible pathologically.]

Distant metastasis (M)

  • MX: Presence of distant metastasis cannot be assessed
  • M0: No distant metastasis
  • M1: Distant metastasis

Find overlapping cases with this tissue array: